Chronic Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Decreases Hypertension, Insulin Resistance, and Hypertriglyceridemia in Metabolic Syndrome
Table 1
Plasma lipid profile in lean and obese SHR-corpulent rats before and after three weeks of treatment with vehicle or compound 11.
Period
Lean SHR-cp vehicle
Lean SHR-cp compound 11
Obese SHR-cp vehicle
Obese SHR-cp compound 11
Total cholesterol (mg/dL)
Baseline
64 ± 2
62 ± 1
122 ± 7#
121 ± 8#
Week 3
74 ± 3
93 ± 3*
154 ± 6#
233 ± 14#*
LDL cholesterol (mg/dL)
Baseline
8 ± 1
9 ± 1
14 ± 1#
15 ± 2#
Week 3
16 ± 1
20 ± 1*
34 ± 2#
HDL cholesterol (mg/dL)
Baseline
21 ± 0
21 ± 1
35 ± 2#
34 ± 1#
Week 3
23 ± 1
25 ± 1*
42 ± 2#
45 ± 2#
Triglycerides (mg/dL)
Baseline
60 ± 4
60 ± 3
516 ± 79#
662 ± 139#
Week 3
62 ± 8
42 ± 3*
654 ± 91#
NEFA (mmol/L)
Baseline
1.6 ± 0.1
1.7 ± 0.1
1.4 ± 0.1
1.4 ± 0.1
Week 3
1.0 ± 0.2
0.7 ± 0.1
1.1 ± 0.1
1.0 ± 0.1
Data are expressed as mean ± SEM. LDL: low-density lipoprotein; HDL: high-density lipoprotein; NEFA: nonesterified fatty acid. * < 0.05 versus vehicle within genotype; # < 0.05 versus lean SHR-cp.
